Odne attracts ZEISS Ventures as investor
17.06.2025
Swiss startup Odne, focused on transforming endodontic care, has raised an additional CHF 4.2 million (USD 5.1 million) in a Series A1 extension round. The financing was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, and supported by existing investors, employees, and several private and dental investors. The funds will be used to support Odne's expansion in the US market.
 |
 |
Founded to address the long-standing challenges of root canal treatments, the Medtech startup Odne is developing a comprehensive technology platform for Root Preservation Therapy (RPT). Its flagship device, OdneClean, received FDA clearance in August 2024 and was introduced to endodontic specialists at AAE 2025 in Boston (American Association of Endodontists). The device employs hydro-dynamic cavitation and sterile water for effective canal debridement.
Odne's platform also includes OdneFill, a light-curable, all-in-one root canal filling material, and OdneCure, an ultra-thin micro-laser for light-curing. Both products were FDA cleared in 2023 and are currently in a Priority Access Program launched in May 2024.
Root canal procedures, which number over 60 million globally each year, have historically seen success rates as low as 46%. Odne aims to raise these standards through its integrated approach. The company had previously secured CHF 4.8 million in the initial closing of its Series A round in March 2024, bringing the total Series A financing to CHF 9 million.
With ZEISS Ventures now on board, Odne is positioning itself to become a key player in next-generation endodontic solutions.
Odne has been ranked among the TOP 100 Swiss startups, partcipated in Venture Leaders, and won Venture Kick.
Odne's team from up left to down right: Mark Bispinghoff (COO & Co-Founder), Barbara Hochstrasser (Quality Manager), Philipp Stücklin (CTO), Silviu Boanta (Development Engineer), Holger Essig (General Manager Europe & Global Marketing), Andreas Schneider (Product Manager), Andreas Schmocker (CEO & Co-Founder), Barbara Kunz (Head Administration), and Else Ellermann (Scientific Affairs Associate)
Odne's platform also includes OdneFill, a light-curable, all-in-one root canal filling material, and OdneCure, an ultra-thin micro-laser for light-curing. Both products were FDA cleared in 2023 and are currently in a Priority Access Program launched in May 2024.
Root canal procedures, which number over 60 million globally each year, have historically seen success rates as low as 46%. Odne aims to raise these standards through its integrated approach. The company had previously secured CHF 4.8 million in the initial closing of its Series A round in March 2024, bringing the total Series A financing to CHF 9 million.
With ZEISS Ventures now on board, Odne is positioning itself to become a key player in next-generation endodontic solutions.
Odne has been ranked among the TOP 100 Swiss startups, partcipated in Venture Leaders, and won Venture Kick.
Odne's team from up left to down right: Mark Bispinghoff (COO & Co-Founder), Barbara Hochstrasser (Quality Manager), Philipp Stücklin (CTO), Silviu Boanta (Development Engineer), Holger Essig (General Manager Europe & Global Marketing), Andreas Schneider (Product Manager), Andreas Schmocker (CEO & Co-Founder), Barbara Kunz (Head Administration), and Else Ellermann (Scientific Affairs Associate)